Hypera (OTCMKTS:HYPMY) Releases Quarterly Earnings Results

Hypera (OTCMKTS:HYPMY) released its earnings results on Thursday. The company reported $0.02 EPS for the quarter, Zacks reports. Hypera had a return on equity of 13.18% and a net margin of 20.04%. The firm had revenue of $258.56 million during the quarter.

Hypera Stock Up 4.7 %

Shares of OTCMKTS HYPMY opened at $3.62 on Friday. The company has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $3.74. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.41 and a current ratio of 1.81. Hypera has a 12 month low of $2.64 and a 12 month high of $6.90.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.